The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App 
Professionals >> Visit The Body PROThe Body en Espanol
  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Clinical Trials

February 27, 2004

Clinical Trials at Swedish Medical Center

Tipranavir Early Access Program

There are limited openings in this program. Please contact Heather Algren at (206) 386-2820.

Protease Inhibitor Study

You may be eligible to join a research study of a medication for HIV disease if you have taken HIV medications in the past that no longer work for you and you are currently taking a combination of HIV medications and your viral load is over 1,000 copies. Please contact Janice Price at (206) 386-2523.

AIDS Clinical Trials Unit (ACTU) Has a New Study!

Correlation Between Drug Levels in the Blood & Resistance Testing

The study will evaluate the correlation between drug blood levels and resistance testing with viral load suppression for each of the three Ritonavir-boosted protease inhibitors.


  • On stable HAART for 90 days, with exposure to NRTI, NNRTI, and PIs
  • HIV RNA of 2,500 copies/mL or above and evidence of RESISTANCE
  • 13 years of age or older
  • Men and Women (Women must not be pregnant)


The study will provide the following PI drug combinations + optimized background regimen of ZDV, 3TC, or Abacavir are chosen as background drugs.

  1. Lopinavir/ritonavir + Ritonavir
  2. Fosamprenavir/ritonavir (The FDA has approved GW-433908, which is a form of Amprenavir that requires fewer pills. However, its use in this trial is investigational)
  3. Indinavir/ritonavir
  4. Tenofovir added at day 15

Study will run for 24 weeks.

Exams and testing provided at no cost. $20 per study visit and $150 for one all-day visit.

Contact Carol Glenn at Madison Clinic or call the ACTU (206)-731-3184 and ask for the screening nurse on call. Thank you.

  • Email Email
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by Seattle Treatment Education Project. It is a part of the publication STEP Ezine.
See Also